SAN DIEGO, Sept. 16 /PRNewswire/ -- Aethlon Medical, Inc. , reported that at its annual meeting of stockholders completed today in San Diego, California, the stockholders re-elected the incumbent four-person Board of Directors.
Shareholders also:
(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)
Based on the preliminary report from the Inspector of Elections, approximately 82.4 percent of outstanding shares were represented at the meeting and each director received affirmative votes from 99.2 percent or more of the shares voted. Shareholders also ratified Squar, Milner, Peterson, Miranda & Williamson LLP as Aethlon’s independent accountants, with affirmative votes from approximately 99.4 percent of the shares that were represented at the meeting. Shareholders ratified the measure to increase the limit on authorized shares, with affirmative votes from approximately 93.0 percent of the shares that were represented at the meeting.
Final vote totals will be included in the company’s quarterly report for the fiscal quarter ending September 30, 2009 to be filed with the United States Securities and Exchange Commission.
Jim Joyce, Chairman and Chief Executive Officer of Aethlon Medical, Inc. said, “We truly appreciate the overwhelming support received from our shareholders.”
About Aethlon Medical, Inc.
Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.
Forward-looking Statements
This release contains forward-looking statements which reflect management’s current views of future events and operations including but not limited to estimates of financial performance and cash flows, trends in subscriber preference and engagement and results of marketing strategies. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include the risk of changing economic conditions, the impact of executive management transitions, failure of product demand or market acceptance of both existing and new products and services and the impact of competitive products and pricing. Please see Aethlon Medical, Inc.'s recent filings with the Securities and Exchange Commission for information about these and other risks that may affect the Company. All forward-looking statements included in this release are based on information available to us on the date hereof. These statements speak only as of the date hereof, and Aethlon Medical, Inc. does not undertake to publicly update or revise any of its forward-looking statements, even if experience or future changes show that the indicated results or events will not be realized.
SOURCE Aethlon Medical, Inc.
CONTACT: Jon Cunningham of RedChip Companies Inc., +1-407-644-4256, cell,
+1-407-491-4498, Jon@redchip.com, for Aethlon Medical, Inc.; or Jim Joyce,
Chairman, CEO, +1-858-459-7800, ext. 301, jj@aethlonmedical.com, or Jim
Frakes, Senior VP Finance, +1-858-459-7800, ext. 300,
jfrakes@aethlonmedical.com, both of Aethlon Medical, Inc.
Web site: http://www.aethlonmedical.com/
